ID   OV-UL-2
AC   CVCL_X963
SY   OVarian-ULm-2
DR   cancercelllines; CVCL_X963
DR   Wikidata; Q54936875
RX   PubMed=11242531;
RX   PubMed=15153938;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Unspecified (PubMed=15153938).
DI   NCIt; C4908; Ovarian carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 19-12-24; Version: 10
//
RX   PubMed=11242531; DOI=10.1089/10430340150504019;
RA   Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J.,
RA   Kreienberg R., Runnebaum I.B.;
RT   "Adenoviral transduction efficiency of ovarian cancer cells can be
RT   limited by loss of integrin beta3 subunit expression and increased by
RT   reconstitution of integrin alphaVbeta3.";
RL   Hum. Gene Ther. 12:391-399(2001).
//
RX   PubMed=15153938; DOI=10.1038/sj.cgt.7700727;
RA   Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.;
RT   "Cooperative effect of adenoviral p53 gene therapy and standard
RT   chemotherapy in ovarian cancer cells independent of the endogenous p53
RT   status.";
RL   Cancer Gene Ther. 11:547-554(2004).
//